Studio sugli effetti anticancerogeni della melatonina nei tumori al polmone (NSCLC) e sue possibili applicazioni terapeutiche

In questo studio, pubblicato su Oncotarget , sono state analizzati, con risultati positivi, gli effetti anticancerogeni della melatonina sui tumori al polmone non a piccole cellule. Il carcinoma polmonare non a piccole cellule (NSCLC) è anche chiamato adenocarcinoma o carcinoma squamocellulare. Secondo l'American Cancer Society (ACS), è il tumore polmonare più diffuso, che corrisponde all'85-90% di tutte le diagnosi di cancro al polmone (dati ACS, 2012). Non cresce rapidamente come il carcinoma polmonare a piccole cellule.

Melatonin as a potential anticarcinogen for non-small-cell lung cancer.

Oncotarget. 2016 Apr 18;

Authors: Ma Z, Yang Y, Fan C, Han J, Wang D, Di S, Hu W, Liu D, Li X, Reiter RJ, Yan X

Abstract
Non-small-cell lung cancer (NSCLC) is a leading cause of death from cancer worldwide. Melatonin, an idoleamine discovered in the pineal gland, exerts pleiotropic anticancer effects against a variety of cancer types. In particular, melatonin may be an important anticancer drug in the treatment of NSCLC. Herein, we review the correlation between the disruption of the melatonin rhythm and NSCLC incidence; we also evaluate the evidence related to the effects of melatonin in inhibiting lung carcinogenesis. Special focus is placed on the oncostatic effects of melatonin, including anti-proliferation, induction of apoptosis, inhibition of invasion and metastasis, and enhancement of immunomodulation. We suggest the drug synergy of melatonin with radio- or chemotherapy for NSCLC could prove to be useful. Taken together, the information complied herein may serve as a comprehensive reference for the anticancer mechanisms of melatonin against NSCLC, and may be helpful for the design of future experimental research and for advancing melatonin as a therapeutic agent for NSCLC.

PMID: 27102150 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/27102150?dopt=Abstract